金茵利胆胶囊的体外抗炎活性评价及其谱效关系研究

目的 评价金茵利胆胶囊的体外抗炎活性,并研究其抗炎谱效关系。方法 建立LPS诱导的RAW264.7细胞炎症模型,通过检测细胞上清中NO、TNF-α和IL-6等指标的含量来评价金茵利胆胶囊的抗炎活性。在此基础上,采用均匀设计法制备金茵利胆胶囊组成饮片的不同配伍样本,采用高效液相法建立均匀设计样品的指纹图谱,对均匀设计样品进行抗炎活性测定;以细胞上清液中NO、TNF-α和IL-6的抑制率为药效指标,与共有峰峰面积经灰色关联分析构建抗炎谱效关系。结果 金茵利胆胶囊提取物（0.25~1.00 mg/mL）能显著降低LPS诱导的RAW264.7细胞分泌NO、TNF-α和IL-6。经对照品比对指认出其中7个色谱峰,分别为新绿原酸（9号峰）、绿原酸（13号峰）、隐绿原酸（14号峰）、1, 3-二咖啡酰奎宁酸（16号峰）、对羟基苯乙酮（17 号峰）、柚皮苷（21 号峰）、新橙皮苷（23 号峰）。抗炎谱效关系结果表明,共有峰均具有一定的抗炎贡献度,其中共有峰峰21（柚皮苷）、峰23（新橙皮苷）与3个细胞炎症指标的关联度均大于0.74。结论：金茵利胆胶囊发挥抗炎作用是多种成分共同作用的结果,为金茵利胆胶囊抗炎药效物质基础及其质量控制提升提供参考。     

Isolation and Structure Elucidation of Neokadsuranic Acid A, the First Triterpenoid with the 14 (13-->12) abeo Lanostane Skeleton, and (24Z)-3-Oxo-lanosta-8,24-dien-26-oic Acid1

Neokadsuranic acid A, which is the first triterpenoid with the 14(13-->12) ABEO lanostane skeleton, was isolated from KADSURA HETEROCLITA together with (24 Z)-3-oxo-lanosta-8,24-dien-26-oic acid. The present paper deals with the isolation and structure elucidation of these two new compounds.     

Ser80Ile mutation and a concurrent Pro25Leu variant of the <Emphasis Type="Italic">VHL</Emphasis> gene in an extended Hungarian von Hippel-Lindau family

Von Hippel-Lindau disease (VHL) is a rare autosomal dominant disease characterized by development of cystic and tumorous lesions at multiple sites, including the brain, spinal cord, kidneys, adrenals, pancreas, epididymis and eyes. The clinical phenotype results from molecular abnormalities of the VHL tumor suppressor gene, mapped to human chromosome 3p25-26. The VHL gene encodes two functionally active VHL proteins due to the presence of two translational initiation sites separated by 53 codons. The majority of disease-causing mutations have been detected downstream of the second translational initiation site, but there are conflicting data as to whether few mutations located in the first 53 codons, such as the Pro25Leu could have a pathogenic role. In this paper we report a large Hungarian VHL type 2 family consisting of 32 members in whom a disease-causing AGT80AAT (Ser80Ile) c.239G>A, p.Ser80Ile mutation, but not the concurrent CCT25CTT (Pro25Leu) c.74C>T, p.Pro25Leu variant co-segregated with the disease. To our knowledge, the Ser80Ile mutation has not been previously described in VHL type 2 patients with high risk of pheochromocytoma and renal cell cancer. Therefore, this finding represents a novel genotype-phenotype association and VHL kindreds with Ser80Ile mutation will require careful surveillance for pheochromocytoma. We concluded that the Pro25Leu variant is a rare, neutral variant, but the presence such a rare gene variant may make genetic counseling difficult.     

Corporate response to the HIV/AIDS epidemic in Uganda - time for a paradigm shift?

The HIV/AIDS epidemic is likely to remain the pre-eminent global health concern for the foreseeable future. In Uganda, while significant progress has been made by the government over the past decade in bringing down the rate of new infections, the HIV/AIDS burden in the country remains huge and vigilant efforts must be continued if this burden is to further decrease.

Traditionally the government, supported by its international partners as well as local non-government organizations and the community has borne the brunt of the costs of containing the epidemic in Uganda. While the corporate sector in the country has financially contributed towards the costs of some of the interventions that are currently in place to combat the HIV epidemic, there is largely a paucity of sustained and systematic corporate leadership in providing comprehensive HIV/AIDS programmes for their employees.

A survey done by the authors of this paper reveals that most programmes undertaken in the private sector are of limited scope. We argue that there is more the corporate sector can do to more equitably share the HIV/AIDS burden, without necessarily jeopardizing its primary role - namely to maximize returns to shareholders.

This paper proposes a conceptual framework of how companies can approach the issue of HIV/AIDS within their workforce and suggests that providing more comprehensive interventions may in some instances result in substantial cost savings through the prevention or at least delay of HIV/AIDS related consequences such as: frequent absences from work, erosion of company skills and knowledge through key employee deaths, and the costs of hiring and training replacements etc. This ultimately could result in positive financial returns to those companies that choose to pursue work place led HIV/AIDS control and prevention programmes.

     

我院2004年～2006年6月抗感染药物应用分析

目的 了解我院2004年～2006年6月抗感染药物的应用情况，分析抗感染药物使用的特点和趋势。为其合理应用和科学管理提供依据。方法 对我院2004年～2006年6月抗感染药的销售金额排序。并采用WHO药物统计合作中心设定的限定日剂量（defined daily dose，DDD）方法计算我院抗茵药物的用药频度。结果 我院临床较常用的抗感染药物为头孢菌素类、青霉素类、大环内酯类、喹诺酮类；2004年～2006年6月我院抗感染药物消耗金额，在年度药品消耗总金额中，都排在临床用药第1位：但比例逐年下降；大部分抗感染药物日均费用逐年递减。结论 2004年-2006年6月我院抗感染药物使用基本合理．新上市的抗感染药物以及药品价格昂贵的抗感染药物使用较少。     

华南、华北人群HLA-DQB1等位基因多态性

目的从基因水平调查了中国华南、华北地区人群HLA-DQB1等位基因频率，并研究比较两地区人群HLA-DQB1多态性分布。方法采用深圳益生堂生物企业有限公司研制开发的“HLA-DQB1低分辨率分型基因芯片检测试剂盒”，应用聚合酶链反应．序列特异性引物＋序列特异性寡核苷酸探针芯片检测技术，对700名南方地区的中国人和320名北方地区的中国人进行基因分型。结果鉴定了10个HLA-DQB1等位基因，获得了一组准确、科学的统计数据。结论得到了中国华南、华北地区人群HLA-DQB1等位基因频率差异的数据，证明中国人群HLA-DQB1＊02，05，0601，0602，0603的分布南北差异有统计学意义（P〈0．05），为疾病相关性研究、人文科学研究提供了可靠的遗传学数据。     

抗α-玉米赤霉醇单克隆抗体的研制及初步应用

目的:制备抗α-玉米赤霉醇(α-ZER)的单克隆抗体(mAb),建立对动物源性食品中残留α-ZER及其同系物的检测方法。方法:结合O-羧甲基羟胺法和EDC法制备α-ZER-BSA偶联物,免疫BALB/c小鼠,采用杂交瘤技术制备mAb。用夹心ELISA测定mAbIg亚类;按Beatty法计算亲和常数;间接ELISA法测定效价;用直接竞争ELISA检测mAb与α-ZER的同系物、己烯雌酚、19-去甲睾酮、链霉素及氯霉素等的交叉反应;绘制α-ZER标准品竞争抑制曲线,检定抗体的灵敏度。用该抗体建立的直接竞争ELISA对37份动物肝组织样品进行检测,并与HPLC检测结果比较。结果:紫外线扫描证明,α-ZER-BSA偶联成功。实验获得8株可稳定分泌抗α-ZERmAb杂交瘤细胞株,其中1株(4E5)分泌的mAb效价较高,为5.142×107,其Ig亚型为IgG1。该mAb能特异识别α-ZER及其同系物,而与其它常用兽药无交叉反应。建立了α-ZER直接竞争ELISA,从HPLC确认为阴性的37份样品中,筛出8份阳性样品。结论:利用mAb建立的直接竞争ELISA检测方法,适合动物源性食品中残留α-ZER及其同系物的快速筛选。     

Hydrophobic adherence and phase variation in Bordetella pertussis

The hydrophobicity of Bordetella pertussis was assayed by measuring the ability of cells in suspension to adhere to a polystyrene surface. The quantity of adhered bacteria was measured by the binding of enzyme-conjugated anti B. pertussis antibodies. Hydrophobic adherence of non-pathogenic variant strains was about 20% of that exhibited by pathogenic strains. Hydrophobicity was a stable trait as it did not change with passaging or storage. Assays of a series of characterized stable variants suggested that the Filamentous Hemagglutinin (FHA) is the cell surface moiety responsible for hydrophobic adherence in B. pertussis.     

医疗器械临床评价常见误区浅析

《医疗器械临床评价技术指导原则》中提出的三种临床评价路径,对每一种评价路径都有着明确的指引和要求,申请人根据不同的评价路径提供相应的临床评价证据来评价产品的安全有效性,但是在实操过程中仍有不少对临床评价理解的误区,本文将对其中常见的误区进行浅析。     

健康指数构建的统计分析流程及实现

  目的  基于综合评价理论探索并归纳健康指数构建的统计分析流程,开发相关R包用于软件实现,为健康指数研究开发一套快捷高效的评价工具,实现一键生成高度集成的综合指数及评价结果,以期为监管部门提供科学可靠的评价信息与决策依据。  方法  使用R 4.1.3软件开发EvaModels包,结合健康指数构建的统计分析流程对EvaModels包内各项函数进行整体介绍与参数解释,分析比较各类方法的适用场景,并以公立医院持续发展指数构建为例进行演示分析。  结果  健康指数构建包括确定指数研究主题、构建评价指标体系、多指标综合评价及评价结果可视化四大流程。所开发的EvaModels包共内置九个函数,通过多种方法实现指标筛选、数据标准化、指标赋权和综合评价等功能,可满足多种评价问题的分析需求,基本覆盖健康指数构建的统计分析流程。  结论  EvaModels包通过一组函数将健康指数构建中涉及统计分析的工作流程自动化、简单化,过程与代码易于解读与调用,提高了健康指数构建的便捷性和可操作性。